AMAG Pharmaceuticals (AMAG) Earns Neutral Rating from Analysts at B. Riley

Analysts at B. Riley started coverage on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note issued to investors on Thursday. The firm set a “neutral” rating and a $16.00 price target on the specialty pharmaceutical company’s stock. B. Riley’s target price indicates a potential upside of 14.70% from the company’s current price.

Other analysts have also issued reports about the company. Piper Jaffray Companies began coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 target price for the company. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Finally, Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $23.38.

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) opened at $13.95 on Thursday. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $36.83. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.

Hedge funds have recently added to or reduced their stakes in the company. Hikari Power Ltd grew its holdings in shares of AMAG Pharmaceuticals by 75.0% in the second quarter. Hikari Power Ltd now owns 70,000 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after acquiring an additional 30,000 shares in the last quarter. Dupont Capital Management Corp grew its holdings in shares of AMAG Pharmaceuticals by 102.8% in the third quarter. Dupont Capital Management Corp now owns 19,731 shares of the specialty pharmaceutical company’s stock valued at $364,000 after acquiring an additional 10,000 shares in the last quarter. Prudential Financial Inc. grew its holdings in shares of AMAG Pharmaceuticals by 35.7% in the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock valued at $13,382,000 after acquiring an additional 190,660 shares in the last quarter. Northern Trust Corp grew its holdings in shares of AMAG Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 464,647 shares of the specialty pharmaceutical company’s stock valued at $8,550,000 after acquiring an additional 26,725 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of AMAG Pharmaceuticals by 94.4% in the third quarter. State Board of Administration of Florida Retirement System now owns 46,075 shares of the specialty pharmaceutical company’s stock valued at $850,000 after acquiring an additional 22,374 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://sportsperspectives.com/2017/12/07/amag-pharmaceuticals-amag-earns-neutral-rating-from-analysts-at-b-riley.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply